Treatment patterns and prognosis of patients with inoperable stage III NSCLC after completion of concurrent chemoradiotherapy ± immune checkpoint inhibition: a decade-long single-center historical analysis.

J Cancer Res Clin Oncol · 2023 · PMC10314870 · PMID 35915184

Europe PMC DOI

hedged sentences

0.0620

closest p · 1.2× alpha

0.0620

boldest claim

The sentences

a clear trendp = 0.062so close (0.05 < p ≤ 0.1)

Furthermore, there was a clear trend toward longer LRRFS [HR 0.497 (95% CI 0.239–1.035, p = 0.062)], PFS [HR 0.571 (95% CI 0.311–1.050, p = 0.071)] and OS [HR 0.447 (95% CI 0.168 1.191, p = 0.100)] in patients treated with ICI.

also in 5,016 other papers

highly significantno p-value reported

While we observed no significant impact on patient outcome in the univariate analysis of the entire cohort, it was highly significant for outcome amongst non-ICI patients.

also in 26,558 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.